Literature DB >> 1596594

Current drug therapy for Parkinson's disease. A review.

R J Coleman1.   

Abstract

The impact of neuropharmacology has been greatest in 2 areas of clinical treatment: epilepsy and Parkinson's disease. This article covers the drug treatment of Parkinson's disease, a condition which characteristically affects the elderly population. The 5 drugs or groups of drugs used in the treatment of Parkinson's disease are: (a) anticholinergic drugs; (b) amantadine; (c) levodopa plus a peripheral decarboxylase inhibitor; (d) dopamine agonists; and (e) selegiline. Levodopa is still the most effective anti-Parkinsonian drug for most patients and is often combined with selegiline which may retard the rate of disease progression. The early use of dopamine agonists (such as bromocriptine) may prevent the subsequent development of response fluctuations. Once fluctuations have developed, they may be helped by the use of slow release levodopa preparations and, in the most severe cases, subcutaneous apomorphine.

Entities:  

Mesh:

Year:  1992        PMID: 1596594     DOI: 10.2165/00002512-199202020-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  67 in total

1.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

2.  Long-term study of pergolide in Parkinson's disease.

Authors:  J Jankovic
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Arch Neurol       Date:  1989-10

5.  Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.

Authors:  J D Parkes; R C Baxter; C D Marsden; J E Rees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-04       Impact factor: 10.154

Review 6.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

7.  Comparison of pergolide and bromocriptine therapy in parkinsonism.

Authors:  P A LeWitt; C D Ward; T A Larsen; M I Raphaelson; R P Newman; N Foster; J M Dambrosia; D B Calne
Journal:  Neurology       Date:  1983-08       Impact factor: 9.910

8.  Lisuride in parkinsonism.

Authors:  J D Parkes; M Schachter; C D Marsden; B Smith; A Wilson
Journal:  Ann Neurol       Date:  1981-01       Impact factor: 10.422

9.  Long-term experience with pergolide therapy of advanced parkinsonism.

Authors:  R Kurlan; C Miller; R Levy; B Macik; R Hamill; I Shoulson
Journal:  Neurology       Date:  1985-05       Impact factor: 9.910

10.  Dopamine: release from the brain in vivo by amantadine.

Authors:  P F Von Voigtlander; K E Moore
Journal:  Science       Date:  1971-10-22       Impact factor: 47.728

View more
  6 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

3.  Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats.

Authors:  G Skuza; Z Rogoz; G Quack; W Danysz
Journal:  J Neural Transm Gen Sect       Date:  1994

4.  Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Authors:  J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

Review 5.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

6.  Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum.

Authors:  S Granveau-Renouf; D Valente; A Durocher; J M Grognet; E Ezan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Apr-Jun       Impact factor: 2.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.